17 June 2019

Study illuminates PrEP treatment pathway and its facilitators and barriers for women in the Bronx

Self-perceived HIV risk, learning about pre-exposure prophylaxis (PrEP) via trusted sources, positive healthcare experiences and health insurance coverage are facilitators of PrEP initiation and continuation for at-risk minority women, according to research conducted in New York City and published in the Journal of the Association of Nurses in AIDS Care. The investigators identified three distinct phases
11 June 2019

My PrEP Story: KUCHENGA (part 2)

When a friend stays over, I notice the flash glance in the morning as I dole out my PrEP meds, hormones and vitamins from my divider and down them with citrus juice. Silence doesn’t ‘always’ speak volumes but in this case it does.
11 June 2019

Study Suggests Widespread PrEP Use Would Take a Big Bite Out of HIV

The study also projected that PrEP use among adult gay and bi men would result in considerable reductions of HIV among adolescents.
6 June 2019

This drug could end HIV. Why hasn't it? (Podcast)

Dr. Robert Grant developed a treatment — a daily pill known as pre-exposure prophylaxis, or PrEP — that could stop the AIDS crisis. We look at why that hasn’t happened.
3 June 2019

Gay men in PROUD trial experienced high rates of intimate partner violence

Screening for intimate partner violence should form part of sexual health services to reach vulnerable gay men.

HIV prevention pill to get insurance benefit in Korea

The government has decided to allow reimbursement for Gilead’s Truvada (tenofovir disoproxil fumarate/emtricitabine) for pre-exposure prophylaxis (PrEP). The Ministry of Health and Welfare on Tuesday said it would grant insurance benefit for Truvada HIV-1 PrEP used for people who are negative in HIV-1 infection but at high risk due to sex with an HIV-positive partner, starting from June 7.

California may make anti-HIV drug available without prescription for 30 days

Democratic Sen. Scott Wiener has proposed a bill that would allow people to receive their first 30 days of PrEP over the counter if they first receive counseling and an HIV test. But the bill faces opposition from the California Medical Association, which represents doctors, and major insurance companies.
2 June 2019

UK's biggest sexual health clinic has just dropped its PrEP prices

PrEP has become more affordable at London’s leading sexual health clinic. The 56 Dean Street clinic opened its PrEP Shop in February last year and provides the HIV preventative medication for those eligible for NHS care. It will cost as little as £17.50 per month.

Is Off-Label HIV Prevention Better Than None?

Rather than prescribe F/TDF as PrEP, Michael Saag, MD said, prescribers should sidestep the brand-name product and instead give their PrEP-eligible patients a generic HIV drug combination that uses lamivudine (3TC) with TDF.
24 May 2019

Q&A: Battling HIV PrEP stigma with Rep. Brian Sims

To combat the stigma surrounding PrEP use, Pennsylvania state Rep. Brian Sims, D-Philadelphia, the first openly gay man to be elected to the Pennsylvania legislature, recently shared a photo of himself holding an FTC/TDF pill on Instagram.
24 May 2019

The truth is you can afford the medication that prevents HIV. Here’s how.

It’s not the cost of PrEP that keeps more patients from accessing it; it’s the lack of awareness and the daunting nature of our complicated healthcare system.
17 May 2019

Being black and gay: how intersectional stigma impacts on the uptake of PrEP

Qualitative research published in the July issue of Social Science & Medicine by Dr Katherine Quinn and colleagues at the Center for AIDS Intervention Research highlights how intersectional stigma contributes to low pre-exposure prophylaxis (PrEP) uptake for black men who have sex with men (MSM) in the US. Mistreatment in healthcare services, racism, homophobia and
1 May 2019

Opposites Attract study: HIV-positive/negative couples used multiple strategies to prevent HIV transmission

Two years ago, the Opposites Attract study found no transmissions between 343 regular gay couples of differing HIV status where the HIV-positive partner had a viral load under 200 copies/ml, the negative partner was not taking pre-exposure prophylaxis (PrEP), and they did not use a condom. In doing so, alongside the PARTNER study, it
15 April 2019

PrEP should be offered urgently to gay men with a recent STI or multiple condomless partners

Analysis of men who acquired HIV in the deferred arm of the PROUD study highlights two risk factors that are far more important than any others. “A recent history of syphilis or rectal chlamydia/gonorrhoea, or multiple ncRAI [receptive anal intercourse without a condom] partners indicates a high imminent risk of HIV infection,” Ellen White
9 April 2019

Racism, marginalisation and PrEP stereotypes affect PrEP uptake for black MSM in London

Black men who have sex with men (MSM) in London experience a unique set of motivations and barriers to using pre-exposure prophylaxis (PrEP), according to the results of a recent qualitative study published in Sexually Transmitted Infections. This research was carried out by T. Charles Witzel and colleagues at the London School of Hygiene and
7 April 2019

English clinic survey finds that 40% of gay men with new hepatitis C infections are HIV negative

A study of gay and bisexual men diagnosed with recently acquired hepatitis C infection and treated in three English clinics has found that 40% of them were HIV negative, the 25th Annual Conference of the British HIV Association (BHIVA) was told in Bournemouth this week, though all the HIV-negative men were in London.Daniel Bradshaw of
5 April 2019

Raltegravir plus lamivudine is likely to work as PrEP

A combination of the drugs raltegravir and lamivudine produced acceptable drug levels in both women and men, in rectal and vaginal tissues, suggesting that the two drugs could provide an effective alternative to tenofovir-based pre-exposure prophylaxis (PrEP), the 25th Annual Conference of the British HIV Association (BHIVA) heard in Bournemouth yesterday.Dr
2 April 2019

First year of PrEP in Scotland: more users than expected, few dropouts, few HIV infections

The recent report on the first year of the implementation of  pre-exposure prophylaxis (PrEP) through the National Health Service (NHS) in Scotland concludes: “Year one has been a resounding success in terms of establishing a new nationwide service – the first of its type in the UK and one of the first worldwide.” In
19 March 2019

Urine test can provide accurate point-of-care results about PrEP adherence

A point-of-care urine test can accurately determine if a person is adherent to tenofovir-based pre-exposure prophylaxis (PrEP), according to research presented to the recent Conference on Retroviruses and Opportunistic Infections (CROI 2019) in Seattle. The test checks for antibodies to tenofovir and was tested in a trial of 30 people in Thailand who
13 March 2019

TAF: Quick-dissolve combination PrEP insert is effective against HIV infections in monkeys; intermittent solo pill less so

Two studies in monkeys of experimental pre-exposure prophylaxis (PrEP) regimens featuring the drug tenofovir alafenamide (TAF) produced differing results when presented at last week’s Conference on Retroviruses and Opportunistic Infections (CROI 2019) in Seattle. As a third study suggested, the results may partly be due to the way TAF is absorbed into cells. TAF